Experience:
No experience
Employment Type:
Intern/Co-op
Posted:
3/14/2019
Job Category:
Education
Intern: Computational Biology
(This job is no longer available)
Biogen Idec | Cambridge, MA
loading
loading
School
Major
Grad Date
 
 

Not sure what types of jobs you are interested in?


Explore Jobs
Based on Your Education

Follow This Company
Share

Job Description

Job Description

HTVC has been working on the integration of human molecular data, and the intern will contribute to this project by processing and analyzing both internal and external data sets, including RNA expression and protein-protein interaction network, and potentially epigenetics data. The person will be exposed to multiple different computational methods for profiling data analysis, pathway analysis, and data integration. From this analysis, the intern will aid prioritizing target genes for neurodegenerative disease, and also assist establishing therapeutic hypothesis.

Qualifications

Job function

Required:

* Experience in computational biology or bioinformatics research
* Programming in R
* Communication skills, verbal and writing.

Preferred:

* Experience in splice analysis
* Experience in RNA , proteomics, or epigenetics data processing
* Experience in building combined table of mulit-modal data sets.

Legal criteria

* Legal authorization to work in the U.S.
* Enrollment in a full-time undergraduate or graduate program, returning to the academic program following Biogen Intern or Co-op assignment
* Minimum grade point average of 3.2 preferred
* At least 18 years of age prior to the scheduled start date
* Completed at least one year of undergraduate studies

Education

Required: Finishing masters or higher degree in computational biology, bioinformatics, or in related fields.

Preferred: Ph.D. candidate in computational biology, bioinformatics, systems biology or in related fields.

About Biogen Idec

Biogen Idec Inc. is engaged in the development, manufacturing, and commercialization of therapies. The Company's products address diseases such as multiple sclerosis, lymphoma and rheumatoid arthritis. The Company has four products: AVONEX (interferon beta-1a), RITUXAN (rituximab), TYSABRI (natalizumab) and FUMADERM (dimethylfumarate and monoethylfumarate salts). AVONEX is used in the treatment of relapsing forms of multiple sclerosis (MS). RITUXAN is used in the treatment of relapsed or refractory low-grade or follicular, CD20-positive, and B-cell, non-Hodgkin's lymphomas (B-cell NHLs). TYSABRI is approved for the treatment of relapsing forms of MS. FUMADERM acts as an immunomudulator. It also has product candidates, such as BG-12 (acquired with the purchase of Fumapharm), ANTI-CD80 antibody/(galiximab), ANTI-CD23 antibody/(lumiliximab), Ocrelizumab/(Humanized ANTI-CD20 Antibody) and Lixivaptan.In January 2007, the Company completed the acquisition of Syntonix Pharmaceuticals, Inc. (Source: 10-K)